HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds
Provided herein are HER2-targeting molecules comprising Shiga toxin A Subunit derived polypeptides having 1) de-immunization and 2) reduced, protease-cleavage sensitivity while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity via ribosome inhibition. Certain HER2-targeting molecules of the present invention exhibit reduced immunogenic potential in mammals and are well-tolerated by mammals while retaining aforementioned features. The HER2-targeting molecules of the present invention have uses for selectively killing specific cells (e.g., HER positive tumor cells); for selectively delivering cargos to specific cells (e.g., HER positive tumor cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving the expression or over-expression of cell-surface HER2.
1. A method of treating a disease, disorder, or condition involving HER2-expressing cells in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a HER2-targeting molecule comprising a polypeptide sequence of SEQ ID NO: 29 or SEQ ID NO: 102, and at least one pharmaceutically acceptable excipient or carrier, wherein the patient is refractory to treatment with at least one dual tyrosine kinase inhibitor or anti-HER2 monoclonal antibody prior to administration of the HER2-targeting molecule.
2. The method of claim 1 , wherein the method further comprises administering to the patient in need thereof a therapeutically effective amount of at least one additional dual tyrosine kinase inhibitor or anti-HER2 monoclonal antibody, wherein the at least one additional dual tyrosine kinase inhibitor or anti-HER2 monoclonal antibody is administered simultaneously or sequentially with the HER2-targeting molecule.
3. The method of claim 2 , wherein the at least one anti-HER2 monoclonal antibody binds an antigenic determinant in HER2 that does not overlap with the antigenic determinant in HER2 bound by the HER2-targeting molecule.
4. The method of claim 1 , wherein the at least one pharmaceutically acceptable excipient or carrier is selected from citrate, sorbitol, polysorbate 20, chloride, and sodium.
5. The method of claim 1 , wherein the at least one dual tyrosine kinase inhibitor or anti-HER2 monoclonal antibody is selected from lapatinib, neratinib, trastuzumab, and pertuzumab.
6. The method of claim 2 , wherein the at least one dual tyrosine kinase inhibitor or anti-HER2 monoclonal antibody is selected from lapatinib, neratinib, trastuzumab, and pertuzumab.